Novo Nordisk is expanding its interest in stem cells to a new disease area through the new agreement with Heartseed.
The collaboration revolves around HS-001, a cardiovascular disease treatment candidate which will be tested in patients with heart failure caused by ischemic heart disease in the second half of 2021.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.